Osaka, Japan

Michiyo Mochizuki

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 7.7

ph-index = 4

Forward Citations = 74(Granted Patents)


Location History:

  • Osaka, JP (2011 - 2014)
  • Kanagawa, JP (2013 - 2022)
  • Fujisawa Kanagawa, JP (2021 - 2023)

Company Filing History:


Years Active: 2011-2024

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Michiyo Mochizuki: Innovator in Cyclic Dinucleotide Development

Introduction

Michiyo Mochizuki is a prominent inventor based in Fujisawa, Kanagawa, Japan. He is affiliated with Takeda Pharmaceutical Company Limited, where he has made significant contributions to the field of pharmaceutical innovation. With one patent to his name, he has demonstrated dedication to the advancement of medical science.

Latest Patents

Mochizuki is credited with a patent titled "Methods of making a cyclic dinucleotide." This patent describes a compound that exhibits STING (Stimulator of Interferon Genes) agonistic activity, which holds promise for the development of therapies aimed at preventing or treating STING-related diseases. The patent outlines a compound represented by a specific formula, as detailed in the patent description, or its salt forms.

Career Highlights

Throughout his career at Takeda Pharmaceutical Company Limited, Mochizuki has worked on groundbreaking research that bridges the gap between innovative biological compounds and therapeutic applications. His expertise in pharmaceutical development has played a vital role in propelling the company’s research initiatives forward.

Collaborations

Mochizuki collaborates closely with esteemed colleagues such as Masato Yoshikawa and Morihisa Saitoh. Their collective efforts in research and development have fostered advancements in the understanding of cyclic dinucleotides and their potential therapeutic benefits.

Conclusion

Michiyo Mochizuki's contributions to the field of pharmaceuticals through his innovative patent highlight the importance of research in addressing modern medical challenges. His dedication to developing new therapeutic agents reflects a commitment to improving health outcomes and advancing scientific knowledge in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…